PLK1 and neoplasm: In addition to in vitro studies, we demonstrated in in vivo models of RMS and NB that the PLK1 inhibitor BI 2536 cooperates with VCR or eribulin, respectively, to significantly suppress tumor growth compared to either drug alone [45–47].